Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Enthusiasm on social media, driven largely by celebrities and influencers, over their use for weight loss has led to a global shortage
By the fourth day without these probiotics, my hunger level reminded me it was time to get back into my routine
Purposely vague
If you're on a plant-based diet or don't eat fortified foods containing B12, supplementation can be a simple, effective way to get vitamin B12 and support your weight loss goals while on Ozempic therapy
The FDA also warns not to take Rybelsus if you have a personal or family history of multiple endocrine neoplasia syndrome Type 2, medullary thyroid cancer, or insulin-dependent diabetes
Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,695 followers
